Scaling up synthesis of Colorado State University's fluoroalkylphosphines

这个可行性项目代表了一个机会，种子一个新的合作伙伴关系，使皮质有机有限公司可以成为新的商业生产商，专利申请中的化学品从科罗拉多州立大学。这些化学品在药物发现和农用化学品研发方面具有潜在的用途，如果这些化学品能够在商业上可行的基础上以有用的数量供应，世界各地的研究人员可能有兴趣研究它们的特性。如果这个可行性项目成功，并最终发现在商业上可行的基础上生产这些化学品的新方法，那么Cortex Organics就可以成为这些化学品的全球供应商或全球独家供应商，供研发实验室使用。如果这些化学物质被发现可用于新药或农用化学品，那么Cortex Organics可能会发现自己拥有用于大规模生产的关键知识产权。科罗拉多州立大学的Andrew McNally教授和他的团队最近开发了一套工作台稳定的氟烷基膦，其直接将C-H键（在药物样分子中）转化为氟烷基衍生物[Zhang et al.，Nature，2021年4月\]。这在向含有三氟甲基（CF 3）和二氟甲基（CF2 H）基团的新候选药物的总体行业趋势的背景下是重要的。氟代烷基膦在制造这些新的候选药物中特别有用，并且提供了它们可以在候选药物合成过程的后期应用的优点。Cortex与McNally教授联系，提出自己是McNally教授工作的第一阶段商业开发的商业合作伙伴：生产\> 50克批量用于商业销售给有机化学研究人员。Cortex Organics是开发化学品生产新合成方法的专家，在公司短暂的历史中发现了100多种创新的合成方法。Cortex已经通过其网站提供各种化学品进行商业销售，并开发和销售合成工艺给其他制造商。该公司处于有利地位，可以帮助开发氟烷基膦试剂的这些令人兴奋的新发展。这项可行性研究将提供必要的喘息空间，使Cortex团队能够调查和评估进入这一市场的可能性，并为Cortex和科罗拉多州立大学之间正在萌芽的对话注入真实的价值和动力。

This feasibility project represents an opportunity to seed a new partnership whereby Cortex Organics Ltd could become the commercial producer of new, patent-pending chemicals from Colorado State University. These chemicals have potential uses in drug discovery and agrochemical R&D, and researchers around the world are potentially interested in investigating their properties, if the chemicals can be supplied in useful quantities on a commercially viable basis.If successful in this feasibility project and ultimately in discovering new ways to produce these chemicals on a commercially viable basis, then Cortex Organics could become a global supplier or the exclusive global supplier of these chemicals to R&D labs. If the chemicals are found to have applications in novel drugs or agrochemical, then Cortex Organics could find itself in possession of critical intellectual property used in large-scale production. This would open up new revenue opportunities such as licensing synthesis methodologies or subcontracting production.Professor Andrew McNally and his team at Colorado State University recently developed a set of bench-stable fluoroalkylphosphines that directly convert C--H bonds (in drug-like molecules) into fluoroalkyl derivatives \[Zhang et al., Nature, April 2021\]. This is important in the context of an overall industry trend toward new drug candidates that contain trifluoromethyl (CF3) and difluoromethyl (CF2H) groups. Fluoroalkylphosphines are particularly useful in manufacturing these new drug candidates and offer the advantage that they can be applied late in the drug candidate synthesis process. Cortex reached out to Prof. McNally to put itself forward as a commercial partner for the first phase of commercial exploitation of Prof. McNally's work: the production of \>50g batch quantities for commercial sale to organic chemistry researchers.Cortex Organics are experts in developing new synthesis methodologies for the production of chemicals, with over 100 innovative new synthesis methods discovered during the company's short history. Cortex already offers various chemicals for commercial sale through its website, and it has developed and sold synthesis processes to other manufacturers. The company is well-placed to help exploit these exciting new developments in fluoroalkylphosphine reagents. This feasibility study will provide essential breathing space allowing the Cortex team to investigate and assess the possibilities around entering this market and inject real value and momentum into the budding dialogue between Cortex and Colorado State University.